3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trialCarel W. le Roux, Aila Rissanen, Ramón Gomis de Barbará et al.|The Lancet|2017Cited by 843
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both CombinedJ. Lundgren, Signe S. Torekov, Charlotte Janus et al.|New England Journal of Medicine|2021Cited by 469
Proteomics reveals the effects of sustained weight loss on the human plasma proteomePhilipp E. Geyer, Matthias Mann, Nicolai J. Wewer Albrechtsen et al.|Molecular Systems Biology|2016Cited by 261
An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the futureSten Madsbad, Jens J. Holst, Urd Kielgast et al.|Diabetes Obesity and Metabolism|2011Cited by 201
GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese WomenEva W. Iepsen, Signe S. Torekov, J. Lundgren et al.|The Journal of Clinical Endocrinology & Metabolism|2015Cited by 187